OS Therapies (OSTX) Accumulated Expenses (2023 - 2026)
OS Therapies' (OSTX) quarterly Accumulated Expenses came in at $1.4 million in Q1 2026, up 510774.44% YoY from N/an in Q1 2025, and up 107746.83% on a QoQ basis from $1279.0 in Q4 2025.
OS Therapies (OSTX) Accumulated Expenses (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Accumulated Expenses data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Accumulated Expenses rose 510774.44% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 510774.44% YoY) and the FY2025 annual result came in at $1279.0, down 98.55% from the prior year.
- Accumulated Expenses grew to $1.4 million in Q1 2026, from $1279.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.4 million in Q1 2026 to a low of $270.0 in Q1 2025.
- A 4-year average of $264884.4 and a median of $86192.5 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses tumbled 99.83% — and 2026, when it surged 510774.44%.
- Tracing OSTX's Accumulated Expenses over 4 years: stood at $7830.0 in 2023, then jumped by 1028.81% to $88386.0 in 2024, then sank by 98.55% to $1279.0 in 2025, then jumped by 107746.83% to $1.4 million in 2026.
- The last three Accumulated Expenses figures came in at $1.4 million (Q1 2026), $1279.0 (Q4 2025), and $395450.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.38 Mn |
| Dec 31, 2025 | 1,279.00 |
| Sep 30, 2025 | 395,450.00 |
| Mar 31, 2025 | 270.00 |
| Dec 31, 2024 | 88,386.00 |
| Jun 30, 2024 | 83,999.00 |
| Mar 31, 2024 | 162,500.00 |
| Dec 31, 2023 | 7,830.00 |